DealsJul 8, 2026, 08:02 AM
60 Degrees Pharma Secures Option for Castanospermine Tick-Borne Disease IP
AI Summary
60 Degrees Pharmaceuticals, Inc. announced an exclusive option agreement with the Florida State University Research Foundation (FSURF) for intellectual property related to castanospermine. This agreement grants the company an exclusive option to negotiate a U.S. license for castanospermine's use in treating Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme disease. The company will use an evaluation period to develop a commercialization strategy, prioritizing prescription drug development over its dietary supplement strategy for castanospermine.
Key Highlights
- Entered exclusive option agreement with Florida State University Research Foundation (FSURF).
- Agreement covers intellectual property for therapeutic development of castanospermine.
- Focuses on Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme disease.
- Grants exclusive option to negotiate an exclusive U.S. license for patented technology.
- Provides an evaluation period for commercialization strategy and development plan.
- Castanospermine is a naturally occurring iminosugar with broad antiviral and immunomodulatory activity.
Price Impact
More from SXTP